Quart Barry D 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Dec 17, 2025
Insider Transaction Report
Form 4
Quart Barry D
Director
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-12-15$10.36/sh+20,129$208,536→ 32,675 total - Sale
Class A Ordinary Share
2025-12-15$41.51/sh−20,129$835,555→ 12,546 total - Exercise/Conversion
Share Option
2025-12-15−20,129→ 0 totalExercise: $10.36Exp: 2028-02-29→ Class A Ordinary Shares (20,129 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.19 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.